In conclusion, the blockade of the B2R signaling by a selective antagonist might restrict the pathological angiogenesis in retinal diseases, reducing the acute inflammatory and angiogenic responses of the vascular endothelium, and the concomitant amplification and propagation through the FGF-2 and VEGF pathway (Figure 6). This evidence concerns the gene FGF2 and Abnormal retinal morphology.